1. PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) Authors: Belada, D.; Kopeckova, K.; Bergua Burgues, J. M.; Stevens, D.; Nowakowski, G. S.; Waldron-Lynch, M.; Hadar, N.; Weirather, J.; Lässig, C.; Blair, D.; Dreyling, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1981 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) Authors: Greil, R.; Kopeckova, K.; Arcaini, L.; Amin, A.; de Graaf, K.; Jegg, A.-M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1983 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗